Hünenberg, Zug, Switzerland
Dedicated & accomplished national, regional & intern. pharmaceutical & diagnostic seasoned leader w/ a track record of 18+ years experience, in Medical Affairs (MA), Clin. Dev. & Transl. Medicine. I demonstrate a deep passion for advancing treatments in CVM, Nephrology,, Oncology, & Critical Care. Unlocking the value of innovative science, I enjoy an ingenious scientific background with 13+ years in Cell & Molec. Biology cresting in a Ph.D., an intern. Post-Doc fellowship, & an Assoc. Professorship. My scientific expertise encompasses a broad range of research areas: Oncology, Bone Metabolism, Immunology & Mesenchymal Stem Cells. I am geared towards continuous learning that gained me an eMBA. I am an aspirational, goal oriented & empathetic professional dedicated to building trust within & beyond organizational boundaries. With a strategic approach, I excel in developing & implementing impactful medical strategies that deliver substantial value to both patients & the business. Accomplishments include: -Led the successful launch of multiple assets in the country & regions, in cardiology & nephrology. -Spearheaded key medical affairs activities: -Internal stakeholder engagement: impactful medical & capability education, medical plans, country gap analysis workshop, evidence generation, cross functional & disease area collaborations Orchestrated global, reg. & loc. alignment & represented EU markets as core member of global MA team ensuring bidirectional effective communication & decision making. -External stakeholder relationship building & collaborations: advisory boards, Delphi project, symposia, customer engagement plans incl. disease state educational website, omnichannel engagement plans incl. 3rd party platforms, external PtP education, NIS, Phase II-IV, IIS, preclinical studies, etc., patient organization engagement, insight gathering, publications Proficient in integrating professional growth with specialized knowledge, employing a systematic & composed approach to tackle the challenges of today’s complex medical landscape. I thrive in a passionate, collaborative & diverse team with an entrepreneurial mindset, creativity, eagerness to find solutions & develop new ideas. I enjoy unlocking the values of innovative science translated into practical treatment options that address unmet medical needs & improve patient outcomes. I am committed to creating a work culture that values optimism, kindness, integrity & honesty. I take great satisfaction in contributing to the development of individuals, helping them achieve their goals and grow.
•Generated EU Pipeline Oncology Medical Plan •Led Monthly Region Medical Affairs Team (RMAT) Meeting, including 19 country pipeline leads covering dissemination of global strategy & tactics, best practice sharing, content & process training •Fostered cross TA (Vaccine & Oncology) collaboration •Initiated regional CRC council AdBoard & Delphi consensus publication •Collaborated with Value Evidence & Outcome (VEO) team & counties on different registry & IIS •Support Global Clinical Operation liaising with countries •Represented EU in pipeline asset Global Medical Affairs (GMAT), VEO, publication, ClinOps, Medical Review, Investigator team meetings
•EU neph. launch team was granted the yearly'Winning Performance Award EU 2023' •Co-led development & execution of EU MA aCKD strategic/tactics, Strat. Implementation Plan •Executed scientific & external engagement strategy e.g. cross TA, ERA EMJ email blast, EMJ interview article, Nephro-update symposia, ERA e-seminars •EU medical lead for Local & EU Evidence Generation (EvGx) activities e.g. Gap analysis workshop, development of EU tactical EvGx Plan, oversaw ISS, SCS & RWE, EvGx Board working group board meetings, •Acted as medical partner to XF region teams, country & global teams to help shape & execute the MA launch plans •Operated as Pub. Accountable Person (PAP) for ERA publication •Represented EU region in GMAT, Integrated Evidence & Value & Evidence Team, Specialty meetings, Global Pub Core team •Ensured Dapro asset teams across 13 EU Midsize Markets had right capacity & capabilities, overseeing their pre-launch activities & plans (Launch Excellence Deep Dive & L-Readiness assessments) •Led content & process training e.g. Monthly Region EU Dapro Medical Meeting, TA & Product training for 3M, Best Practice Sharing, Copyright, Insight gathering training etc. •Provided full visibility & transparency of global, EU & country activities •Medically led Capability Train the Trainer for EU countries •Drove continuous onboard & upskilling for country new joiners •Enabled performance driven culture w/ clear deliverables e.g. KPI paradigm shift development •Provided medical guidance & input into promo engagement strategy, tactics & materials e.g. Content lab approver, Core Claims, Renal Account working, Capability Building Workstream •Supported & collaborated in Dapro Maximisation Program e.g. oRenal Stakeholder Alliance oOmnichannel incl. Social Media, platforms, emails, oPatient Pathway optimization oMarket Access Managed Entry Agreements oCompetitor Simulation & CI •Insight gathering •Encourage Nephro portfolio approach overarching Dapro strategy
EU-Launch Preparation: • Led cross country non interventional study (NIS) • Led successful launch of Disease State Education (DSE) branded campaign incl. DSE congresses: booth, symposia etc. face to face and virtual & internal events • Launched first Vifor’s DSE webpage, first global email blast, cross TA global Newsletter • Led P to P program in close collaboration with steering committee & implementation in the countries • Managed successful AdBoards • Medically drove the generation of global training material for MSLs & Sales Force (e.g. Objection Handler, FAQ etc.) • Cross-functionally created together with Market Access Global Value Dossier and Payer Believe Map & with Marketing commercial material (GBP, e-Detail Aid, Mode of Action Video, patient material etc.) • Medical led the development of Customer Engagement Plan & its digital implementation • Led approval of Investigator Initiated Studies
Major therapeutic areas covered: CV (HF, ACS, Afib) and Critical Care (CC) (Sepsis, Acute Kidney Injury, Glucose) Achievements/Responsibilities -As clin. lead achieved milestone ‘Launch’ for 2 IUs of GDF-15, Clin. Devlpm. Progm. on time & budget -Established an innovative ‘pre-launch Investigator Initiated Study (IIS)’ process that identified in a KOL collaboration new 3rd differentiating IU for GDF-15. Results published in Lancet & in EU Med. Guidelines • Successful intern. AdBoards with highly professional stakeholder management of CC & CV KOLs. Additionally created an environment conducive to new business opportunities (e.g. 4 original IIS started). -Generation of pre- & post launch Product Specification Documents (clin. opinions, med. risk assessmt.) -Developed several study synopses. -60 IISs & publications/year evaluated and IIS implementation with IIS team. -As BM Validation team lead drove the generation of CDP (including TTP1-3) & the acquisition of valuable cohort through ext. collaborations that will allow verification of working hypothesis on BM IUs. -Advanced Intellectual Properties team resulted in highly valued IPs incl. 5 co-authorships -Strong cross-functional support in generation of pricing strategy & cost effectiveness (Market Access), business cases, project fact books for portfolio prio, package inserts & educational materials (Marketing). • Led pioneering PHC Early Devlpm. Progm Project that accomplished milestone ‘Full development’ -Leading the Sub-Study Publication Team of a key post launch clinical study, numerous distinguished articles published in highly ranked journals & in line with the comprehensive publication plan developed. -Development of a novel process of handing out full study data set to Principal Investigators. Study results were integrated into the Medical Affairs- and Marketing Strategy plans. -Integration of a new IU in a newly created CDP in an ongoing early clinical development project.
Major therapeutic areas covered: Metabolic (Diabetes mellitus Type II), Cardiovascular Disease responsibilities for compounds in -Phase IIa/b acute coronary syndrome program compound -Transfer from preclinical to clinical diabetes mellitus type II (define trial design and efficacy parameters, protocol & informed concent author, clinical input to IND, conduct safety data reviews, define analysis plan, crossfunctional interaction and alignment with other departments, contact point medical inquires, input and consolidation into eCDP, TTP, research and prepare descision boards and external meeting presentation, presenter various meetings, lead clinical scientist group, engaged in SMT)